FDA Issues Warning Letter to Nanogen, Says NanoChip System Adulterated and Misbranded | GenomeWeb

NEW YORK, Aug. 19 (GenomeWeb News) - Nanogen disclosed in an SEC filing today that it has received a letter from the US Food and Drug Administration stating that it requires FDA approval to market its NanoChip microarray platform.


Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.